Plain-English translation of NCT05009082 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether women with advanced ovarian cancer benefit from taking alone or combined with after completing chemotherapy. All participants first receive standard chemotherapy ( and ), and then are randomly assigned to one of two maintenance treatment groups to see which approach helps them live longer and stay cancer-free.
Advanced ovarian cancer is difficult to treat, and while chemotherapy is standard care, finding the best way to prevent the cancer from coming back after initial treatment remains a challenge. This trial compares two different maintenance strategies to see if adding a second medication to the treatment plan improves outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You will receive your first chemotherapy cycle, then have your tumor tested for genetic markers to determine which treatment group you'll join. Over the next 6 months, you'll receive 5 more cycles of chemotherapy (sometimes combined with an additional medication depending on your group). After chemotherapy ends, you'll take daily maintenance medication for up to 3 years, with regular clinic visits and blood tests to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Germany